DUBLIN – Shares in Poxel SA rose as much as 32 percent Monday on the back of a partnering deal with Roivant Sciences GmbH, in which it is getting $35 million up front, $15 million in equity investment and potentially $600 million in development, regulatory and commercialization milestones for ex-Asia rights to its oral type 2 diabetes drug imeglimin.